A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules and Placebo in Schizophrenia, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 166 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.
Among the 20 studies testing xanomeline in Schizophrenia, this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 14 in phase 3, and was the 6th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Argentina, Bulgaria and 4 more countries
Ages 18–65
New York State Psychiatric Institute · Sites in United States
Ages 18–50
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Australia, Canada and 8 more countries
Ages 5–17
Bristol-Myers Squibb · Sites in United States, Colombia, Japan and 1 more country
Ages 13–17
Bristol-Myers Squibb · Sites in United States
Ages 18–65
By country, each count listing its studies:
xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 14 · Phase 4 3
First in 2018; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 396 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 178 across the 20 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 20 have an industry lead sponsor. The 7 most frequent:
This study is registered under Karuna Therapeutics, Inc., a Bristol Myers Squibb company, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company is the lead sponsor of 17 studies on the registry; 8 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
21 studies in Schizophrenia by Bristol-Myers Squibb: 8 open now, 9 under way, 4 of them phase 3. Of 12 finished, 9 (75%) have results posted.
Among the 21 studies in Schizophrenia by Bristol-Myers Squibb, this one is the 4th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2021, is one of 13 in phase 3, and was the 7th registered.
Bristol-Myers Squibb’s Schizophrenia studies by the year they started, since 2016.
2 of the studies testing xanomeline in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07423546New York State Psychiatric InstituteA PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia | 2027-04-30 |
| NCT07061288Bristol-Myers SquibbA Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT | 2027-06-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing xanomeline in Schizophrenia, from their registry updates:
Among Bristol-Myers Squibb’s 21 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily [BID]) versus placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The subject has a history of moderate to severe substance use disorder (other than nicotine) within the past 12 months
Subject has a history of treatment-resistant schizophrenia defined as:
a. Failure to minimally respond to 2 adequate courses of antipsychotic drug (APD) pharmacotherapy Note: Failure to minimally respond is defined as persistence symptoms of moderate severity in 2 or more psychotic symptom domains or persistence of severe symptoms in 1 or more psychotic symptom domains despite adequate dose and duration (6 weeks or longer) of APD treatment.
History of symptom instability
a. > 3 psychiatric hospitalizations over the last 12 months or 2 over the last 6 months
Significant or severe medical conditions including pulmonary, cardiovascular, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the Investigator, could jeopardize the safety of the subject or the validity of the study results
Risk for suicidal behavior during the study as determined by the Investigator's clinical assessment and/or C-SSRS as confirmed by the following:
For all male subjects only, any one of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo
Drug pages: Xanomeline · Trospium chloride
KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
Placebo Capsules
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
PANSS Total Score is a clinician administered measure of schizophrenia symptom severity used widely in antipsychotic research. It includes 30 items across 3 subscales: * Positive Symptoms (7 items) assessing excesses or distortions such as hallucinations, delusions, or grandiosity * Negative Symptoms (7 items) assessing diminished function such as social withdrawal or reduced motivation and * General Psychopathology (16 items) capturing broader symptoms like anxiety, depression, guilt, or cognitive impairment Each item is scored from 1 (absent) to 7 (extreme), producing a PANSS Total Score ranging from 30 to 210, with higher scores indicating more severe symptoms. Baseline is defined as the last non missing PANSS Total Score before first dose. This endpoint evaluates change from Baseline to Week 6, with negative values indicating improvement.
Time frame: Baseline to Week 6
Change From Baseline in Personal and Social Performance Scale (PSP) at Week 6
The Personal and Social Performance (PSP) Scale is a clinician administered assessment of personal and social functioning in individuals with schizophrenia. It evaluates functioning across four key dimensions: * Socially useful activities * Personal and social relationships * Self care and * Disturbing and aggressive behaviors The PSP is completed through a structured clinical interview and provides a total score ranging from 1 to 100, using a 6 point severity rating for each domain. Higher PSP scores indicate better personal and social functioning. The endpoint measures change from Baseline to Week 6 in PSP score, with positive values indicating improved personal and social functioning.
Time frame: Baseline to Week 6
Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) at Week 6
Change from baseline in the Clinical Global Impression-Severity (CGI-S) assesses change in overall illness severity over time as rated by the clinician. The CGI-S is a clinician-rated, single-item scale that evaluates the severity of the participant's illness at the time of assessment based on the clinician's total clinical experience with patients with the same diagnosis. Severity is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill), with higher scores indicating greater illness severity (worse outcome). Ratings are based on observed and reported symptoms, behavior, and functioning over the previous 7 days. Change from baseline is calculated as the difference between the CGI-S score at baseline and Week 6, with negative values indicating improvement and positive values indicating worsening.
Time frame: Baseline to Week 6
Change From Baseline in Positive and Negative Syndrome Scale Marder Positive (PANSS M-Pos) Symptom Factor Score at Week 6
Change from baseline in PANSS M-Pos Symptom Factor Score assesses change in the severity of positive symptoms of schizophrenia over time as rated by the clinician. The PANSS is a clinician-administered scale that evaluates symptom severity based on observed and reported symptoms. The PANSS Marder Positive Symptom Factor score is derived from the following PANSS items: Delusions (P1), Hallucinations (P3), Grandiosity (P5), Suspiciousness/Persecution (P6), Stereotyped Thinking (N7), Somatic Concern (G1), Unusual Thought Content (G9), and Lack of Judgment and Insight (G12). Each item is rated on a 7-point scale (1 = absent to 7 = extreme). The PANSS M-Pos factor score is calculated by summing the relevant item scores, with higher scores indicating greater positive symptom severity (worse outcome). Change from baseline is calculated as the difference between the PANSS M-Pos score at baseline and Week 6, with negative values indicating improvement and positive values indicating worsening.
Time frame: Baseline to Week 6
Change From Baseline in Positive and Negative Syndrome Scale Marder Negative (PANSS M-Neg) Symptom Factor Score at Week 6
Change from baseline in PANSS M-Neg Symptom Factor Score assesses change in the severity of negative symptoms of schizophrenia over time as rated by the clinician. The PANSS is a clinician-administered scale that evaluates symptom severity based on observed and reported symptoms. The PANSS Marder Negative Symptom Factor score is derived from the following PANSS items: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive Social Withdrawal (N4), Lack of Spontaneity of Conversation (N6), Motor Retardation (G7), and Active Social Avoidance (G16). Each item is rated on a 7-point scale (1 = absent to 7 = extreme). The PANSS M-Neg factor score is calculated by summing the relevant item scores, with higher scores indicating greater negative symptom severity (worse outcome). Change from baseline is calculated as the difference between the PANSS M-Neg score at baseline and Week 6, with negative values indicating improvement and positive values indicating worsening.
Time frame: Baseline to Week 6
Percentage of Participants Achieving a ≥ 30% Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
The Positive and Negative Syndrome Scale (PANSS) is a clinician administered scale that assesses symptom severity in schizophrenia and includes 30 items across three subscales: 7 positive symptoms, 7 negative symptoms, and 16 general psychopathology symptoms. Each item is scored from 1 (absent) to 7 (extreme), generating a PANSS Total Score ranging from 30 to 210, with higher scores indicating more severe symptoms. This endpoint evaluates the percentage of participants whose Week 6 PANSS Total Score decreased by at least 30% from Baseline, reflecting clinically meaningful improvement.
Time frame: At Week 6
Percentage of Participants With Preference of Medication (POM) at Week 6
The Preference of Medication (POM) is a two item questionnaire assessing the participant's and informant's preference for the current antipsychotic compared with the most recent pre study antipsychotic. It evaluates perceived benefit or worsening relative to prior treatment. The POM uses a 5 point scale: 1 = "much better, I prefer this medication," 2 = "slightly better," 3 = "about the same," 4 = "slightly worse," 5 = "much worse, I much prefer my previous medication." Based on this scale, responses are categorized as Better (scores 1-2) or Same or Worse (scores 3-5) for both participant and informant assessments.
Time frame: At Week 6
| Milestone | KarXT | Placebo |
|---|---|---|
| Started | 197 | 199 |
| Completed | 194 | 198 |
| Not completed | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Milestone | KarXT | Placebo |
|---|---|---|
| Started | 194 | 198 |
| Completed | 161 | 180 |
| Not completed | 33 | 18 |
| Withdrew: Withdrawal by subject | 10 | 8 |
| Withdrew: Protocol violation | 3 | 1 |
| Withdrew: Lost to follow-up | 5 | 1 |
| Withdrew: Physician decision | 4 | 2 |
| Withdrew: Adverse event | 7 | 2 |
| Withdrew: Other reasons | 4 | 4 |
PANSS Total Score is a clinician administered measure of schizophrenia symptom severity used widely in antipsychotic research. It includes 30 items across 3 subscales: * Positive Symptoms (7 items) assessing excesses or distortions such as hallucinations, delusions, or grandiosity * Negative Symptoms (7 items) assessing diminished function such as social withdrawal or reduced motivation and * General Psychopathology (16 items) capturing broader symptoms like anxiety, depression, guilt, or cognitive impairment Each item is scored from 1 (absent) to 7 (extreme), producing a PANSS Total Score ranging from 30 to 210, with higher scores indicating more severe symptoms. Baseline is defined as the last non missing PANSS Total Score before first dose. This endpoint evaluates change from Baseline to Week 6, with negative values indicating improvement.
| Score on a Scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 | -14.3 ± 1.01 | -12.2 ± 0.98 |
The Personal and Social Performance (PSP) Scale is a clinician administered assessment of personal and social functioning in individuals with schizophrenia. It evaluates functioning across four key dimensions: * Socially useful activities * Personal and social relationships * Self care and * Disturbing and aggressive behaviors The PSP is completed through a structured clinical interview and provides a total score ranging from 1 to 100, using a 6 point severity rating for each domain. Higher PSP scores indicate better personal and social functioning. The endpoint measures change from Baseline to Week 6 in PSP score, with positive values indicating improved personal and social functioning.
| Score on a Scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Personal and Social Performance Scale (PSP) at Week 6 | 5.3 ± 0.75 | 5.9 ± 0.73 |
Change from baseline in the Clinical Global Impression-Severity (CGI-S) assesses change in overall illness severity over time as rated by the clinician. The CGI-S is a clinician-rated, single-item scale that evaluates the severity of the participant's illness at the time of assessment based on the clinician's total clinical experience with patients with the same diagnosis. Severity is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill), with higher scores indicating greater illness severity (worse outcome). Ratings are based on observed and reported symptoms, behavior, and functioning over the previous 7 days. Change from baseline is calculated as the difference between the CGI-S score at baseline and Week 6, with negative values indicating improvement and positive values indicating worsening.
| Score on a Scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) at Week 6 | -0.6 ± 0.06 | -0.5 ± 0.06 |
Change from baseline in PANSS M-Pos Symptom Factor Score assesses change in the severity of positive symptoms of schizophrenia over time as rated by the clinician. The PANSS is a clinician-administered scale that evaluates symptom severity based on observed and reported symptoms. The PANSS Marder Positive Symptom Factor score is derived from the following PANSS items: Delusions (P1), Hallucinations (P3), Grandiosity (P5), Suspiciousness/Persecution (P6), Stereotyped Thinking (N7), Somatic Concern (G1), Unusual Thought Content (G9), and Lack of Judgment and Insight (G12). Each item is rated on a 7-point scale (1 = absent to 7 = extreme). The PANSS M-Pos factor score is calculated by summing the relevant item scores, with higher scores indicating greater positive symptom severity (worse outcome). Change from baseline is calculated as the difference between the PANSS M-Pos score at baseline and Week 6, with negative values indicating improvement and positive values indicating worsening.
| Score on a Scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale Marder Positive (PANSS M-Pos) Symptom Factor Score at Week 6 | -5.0 ± 0.36 | -4.2 ± 0.35 |
Change from baseline in PANSS M-Neg Symptom Factor Score assesses change in the severity of negative symptoms of schizophrenia over time as rated by the clinician. The PANSS is a clinician-administered scale that evaluates symptom severity based on observed and reported symptoms. The PANSS Marder Negative Symptom Factor score is derived from the following PANSS items: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive Social Withdrawal (N4), Lack of Spontaneity of Conversation (N6), Motor Retardation (G7), and Active Social Avoidance (G16). Each item is rated on a 7-point scale (1 = absent to 7 = extreme). The PANSS M-Neg factor score is calculated by summing the relevant item scores, with higher scores indicating greater negative symptom severity (worse outcome). Change from baseline is calculated as the difference between the PANSS M-Neg score at baseline and Week 6, with negative values indicating improvement and positive values indicating worsening.
| Score on a Scale | KarXT | Placebo |
|---|---|---|
| Change From Baseline in Positive and Negative Syndrome Scale Marder Negative (PANSS M-Neg) Symptom Factor Score at Week 6 | -3.1 ± 0.33 | -3.0 ± 0.32 |
The Positive and Negative Syndrome Scale (PANSS) is a clinician administered scale that assesses symptom severity in schizophrenia and includes 30 items across three subscales: 7 positive symptoms, 7 negative symptoms, and 16 general psychopathology symptoms. Each item is scored from 1 (absent) to 7 (extreme), generating a PANSS Total Score ranging from 30 to 210, with higher scores indicating more severe symptoms. This endpoint evaluates the percentage of participants whose Week 6 PANSS Total Score decreased by at least 30% from Baseline, reflecting clinically meaningful improvement.
| Percentage of Participants | KarXT | Placebo |
|---|---|---|
| Percentage of Participants Achieving a ≥ 30% Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 | 37.9 | 35.0 |
The Preference of Medication (POM) is a two item questionnaire assessing the participant's and informant's preference for the current antipsychotic compared with the most recent pre study antipsychotic. It evaluates perceived benefit or worsening relative to prior treatment. The POM uses a 5 point scale: 1 = "much better, I prefer this medication," 2 = "slightly better," 3 = "about the same," 4 = "slightly worse," 5 = "much worse, I much prefer my previous medication." Based on this scale, responses are categorized as Better (scores 1-2) or Same or Worse (scores 3-5) for both participant and informant assessments.
| Percentage of Participants | KarXT | Placebo |
|---|---|---|
| Participant Preference: Better (Scores 1-2) | 58.5 | 50.0 |
| Participant Preference: Same or Worse (Scores 3-5) | 41.5 | 50.0 |
| Informant Preference: Better (Scores 1-2) | 64.3 | 52.2 |
| Informant Preference: Same or Worse (Scores 3-5) | 35.7 | 47.8 |
Collected over Participants were assessed for All-Cause Mortality, SAEs and Other AEs from first dose of study medication until study completion (assessed up to approximately 175 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| KarXT | 0/194 (0%) | 2/194 (1%) | 60/194 (30.9%) |
| Placebo | 0/198 (0%) | 3/198 (1.5%) | 16/198 (8.1%) |
| Event | KarXT | Placebo |
|---|---|---|
| Psychotic disorderPsychiatric disorders | 1/194 | 1/198 |
| SchizophreniaPsychiatric disorders | 1/194 | 0/198 |
| VomitingGastrointestinal disorders | 0/194 | 1/198 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/194 | 1/198 |
| Event | KarXT | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 30/194 | 6/198 |
| VomitingGastrointestinal disorders | 22/194 | 2/198 |
| Dry mouthGastrointestinal disorders | 17/194 | 3/198 |
| SomnolenceNervous system disorders | 12/194 | 7/198 |
| Age, Continuous(Years) | KarXT | Placebo | Total |
|---|---|---|---|
| Mean | 41.6 ± 11.26 | 41.8 ± 10.41 | 41.7 ± 10.83 |
| Sex: Female, Male(Participants) | KarXT | Placebo | Total |
|---|---|---|---|
| Female | 70 | 72 | 142 |
| Male | 127 | 127 | 254 |
| Ethnicity (NIH/OMB)(Participants) | KarXT | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 35 | 34 | 69 |
| Not Hispanic or Latino | 161 | 163 | 324 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | KarXT | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 7 | 5 | 12 |
| Black or African American | 78 | 75 | 153 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| White | 99 | 112 | 211 |
| Other | 10 | 5 | 15 |
| Not Reported | 1 | 0 | 1 |
Showing the first 100 of 166 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2021 to primary completion in Mar 2025, 40 months.
Results were first posted in May 2026, 1 year 1 month after primary completion.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 40 months is above that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xanomeline · Trospium chloride
Karuna Therapeutics, Inc., a Bristol Myers Squibb company →